- Home
- CLRO vs SYBX Comparison
CLRO vs SYBX Comparison
Compare CLRO & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRO
- SYBX
- Stock Information
- Founded
- CLRO 1983
- SYBX N/A
- Country
- CLRO United States
- SYBX United States
- Employees
- CLRO N/A
- SYBX N/A
- Industry
- CLRO Radio And Television Broadcasting And Communications Equipment
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLRO Technology
- SYBX Health Care
- Exchange
- CLRO Nasdaq
- SYBX Nasdaq
- Market Cap
- CLRO N/A
- SYBX 16.5M
- IPO Year
- CLRO N/A
- SYBX N/A
- Fundamental
- Price
- CLRO $0.59
- SYBX $1.25
- Analyst Decision
- CLRO
- SYBX
- Analyst Count
- CLRO 0
- SYBX 0
- Target Price
- CLRO N/A
- SYBX N/A
- AVG Volume (30 Days)
- CLRO 200.1K
- SYBX 5.7K
- Earning Date
- CLRO 05-19-2025
- SYBX 03-06-2025
- Dividend Yield
- CLRO 81.83%
- SYBX N/A
- EPS Growth
- CLRO N/A
- SYBX N/A
- EPS
- CLRO N/A
- SYBX N/A
- Revenue
- CLRO $11,386,000.00
- SYBX $8,000.00
- Revenue This Year
- CLRO N/A
- SYBX N/A
- Revenue Next Year
- CLRO N/A
- SYBX N/A
- P/E Ratio
- CLRO N/A
- SYBX N/A
- Revenue Growth
- CLRO N/A
- SYBX N/A
- 52 Week Low
- CLRO $0.45
- SYBX $1.15
- 52 Week High
- CLRO $1.88
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- CLRO 47.43
- SYBX 40.82
- Support Level
- CLRO $0.60
- SYBX $1.27
- Resistance Level
- CLRO $0.68
- SYBX $1.32
- Average True Range (ATR)
- CLRO 0.06
- SYBX 0.05
- MACD
- CLRO -0.01
- SYBX 0.00
- Stochastic Oscillator
- CLRO 19.55
- SYBX 46.15
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.